According to the 13F filing with the Securities and Exchange Commission dated Nov. 12, 2025, ARK Investment Management sold ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

CRISPR Therapeutics AG (CRSP) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of ...

Recent discussions on X about CRISPR Therapeutics (CRSP) have been buzzing with excitement following the company's stock hitting a 52-week high of $62.32 and news of a significant insider purchase by ...

CRISPR Therapeutics (CRSP) recently showcased new preclinical results for its CTX460 therapy, revealing strong gene and mRNA correction in animal models for Alpha-1 Antitrypsin Deficiency. The ...